Live Breaking News & Updates on Achillion Pharmaceuticals James

Depomed Inc (NASDAQ: DEPO) announced Thursday that it will acquire the U.S. rights to the NUCYNTA franchise from Johnson & Johnson (NYSE: JNJ) subsidiary Janssen Pharmaceuticals, Inc. for $1.05 billion.
According to the company’s press release, “The NUCYNTA franchise. Read More.
Don t Miss Any Updates!
News Directly in Your Inbox
Subscribe to: ....

United Kingdom , Christophers James , Edward Tenthoff , Elemer Piros , Janssen Pharmaceuticalsfriday , Janssen Pharmaceuticals Inc , Arrowhead Pharmaceuticals Inc , Depomed Inc , Akebia Therapeutics Inc , Achillion Pharmaceuticals , Hours Center , Johnson Research And License Agreementfriday , Cantor Fitzgerald , European Union , Janssen Pharmaceuticals , Achillion Pharmaceuticals James , Authorization For Long Acting , Viiv Healthcare , What Happened , React To Arrowhead , Janssen Collaboration , Happened Arrowhead , Following Up Akebia , Research And License Agreementfriday , Analyst Color , Starts Achillion ,